Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GGT1 | P19440 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561926 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MEN1CYP1A2KMT2ATHRB | |
| SCHEMBL12503924 | 0.81 | MEN1 (0.39) | ALDH1A1MEN1CYP1A2KMT2ATHRB | |
| SCHEMBL28791221 | 0.79 | FDPS (0.39) | ALDH1A1MEN1CYP1A2KMT2ATHRB | |
| SCHEMBL899527 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MEN1CYP1A2KMT2ATHRB | |
| SCHEMBL27363350 | 0.76 | SMPD1 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28929632 | 0.74 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1HIF1A | |
| SCHEMBL29420199 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| Sulfuric Acid SCHEMBL29720683 | 0.71 | NOS2 (0.44) | ALDH1A1MEN1CYP1A2KMT2ATHRB | |
| SCHEMBL7272260 | 0.71 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL6007753 | 0.70 | GGT1 (0.33) | ALDH1A1MEN1CYP1A2KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516361-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | claimed |
| WO-2018005801-A2 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | VENENUM BIODESIGN LLC (US) | 2018-01-04 | — | — | WO | disclosed |
| CN-102712676-B | There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-102844327-B | Template-fixed peptidomimetics with CXCR7 modulatory activity | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-101516361-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| CN-1269722-A | Method and composition for modulating responsiveness to corticosteroids | BASF AG (DE) | 2000-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | ALDH1A1 1055/4885MEN1 3178/4885CYP1A2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.